Boston Scientific Corp (BSX) 12.54 $BSX
Market Maker Surveillance Report. BSX, SMA, EMC, BX, GCVRZ, PFMT, Bullishly Biased Price Friction For Thursday, September 11th 2014
M2 - 16 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4878 companies with "abnormal" market making, 2401 companies with positive Friction Factors and 2459 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Boston Scientific Corp (NYSE:BSX), Symmetry Medical Inc (NYSE:SMA), EMC Corp (NYSE:EMC), BIOX Corp (NYSE:BX), Sanofi SA (NASDAQ:GCVRZ), (NYSE
FMT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Dallas Jury Awards Transvaginal Mesh Patient $73 Million in Boston Scientific Lawsuit, Baron and Budd Reports
Business Wire - Thu Sep 11, 5:10PM CDT
Earlier this week, a Dallas jury returned a $73 million verdict in favor of a woman who has suffered serious health problems after being implanted with Boston Scientific's Obtryx transvaginal mesh product. Baron and Budd congratulates Matthews & Associates, Freese and Goss, Edwards & de la Cerda and the rest of the trial team on their victory. The firm hopes that this verdict helps to pave the way for positive results in other transvaginal mesh lawsuits. Baron and Budd represents hundreds of women harmed by transvaginal mesh implants.
Texas Jury awards $73 Million in Pelvic Mesh Case, announces Matthews & Associates
PR Newswire - Wed Sep 10, 3:58PM CDT
A 12-person jury on Monday ordered Boston Scientific Corp. to pay a Texas woman $73 million after finding the company negligent in both the design and marketing of its Obtryx transvaginal mesh sling.
Watch for Boston Scientific to Potentially Pullback After Gaining 1.05% Yesterday
Comtex SmarTrend(R) - Wed Sep 10, 3:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.35 to a high of $12.55. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $12.45 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Boston Scientific to Potentially Pullback after Yesterday's 1.05% Rise
Comtex SmarTrend(R) - Wed Sep 10, 3:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.35 to a high of $12.55. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $12.45 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
pSivida Corp. Names James Barry to Board of Directors
Business Wire - Wed Sep 10, 3:00PM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected James J. Barry, Ph.D. to its Board of Directors.
Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014
PR Newswire - Wed Sep 10, 8:00AM CDT
Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in interventional cardiology. The company will share results from more than a dozen clinical studies at the 26th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation, being held this year in Washington, D.C. from September 13-17.
Market Maker Surveillance Report. WEN, BSX, MO, BA, MSFT, ORCL, Highest Net Buy Volume With Lowest Price Friction For Tuesday, September 9th 2014
M2 - Wed Sep 10, 3:39AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4670 companies with "abnormal" market making, 1404 companies with positive Friction Factors and 3746 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Tuesday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Wendy's Company (NASDAQ:WEN), Boston Scientific Corp (NYSE:BSX), Altria Group Inc (NYSE:MO), Boeing Co (NYSE:BA), MICROSOFT CORPORATION (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Halloran Consulting Group Expands Services with Physician, Safety Expert, and Head of Regulatory Affairs
Business Wire - Tue Sep 09, 9:00AM CDT
Halloran Consulting Group, Inc. (Halloran) today announced the recent hiring of Greg Shipp, MD, formerly with Regenesis Biomedical where he served as Director of Clinical Research; Laura Giannini, RPh, MBA, previously with Boston Scientific as Director of Process Management; and Mary Matthew, formerly with ZIOPHARM Oncology where she served as Vice President of Regulatory Affairs and Quality.
Coronary Stents Market in India 2014
M2 - Tue Sep 09, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qnbgv/coronary_stents) has announced the addition of the "Coronary Stents Market in India 2014" report to their offering. Advancements in technology has resulted in patients being more receptive towards stent implants. The products available in the market can be divided into two types - those manufactured by MNCs and commanding high prices, and those manufactured by domestic companies and generally having lower prices. The general perception is that stents manufactured by MNCs are superior in terms of quality and efficacy whereas those manufactured by domestic companies fail to attain similar high quality. As a result, the MNCs serve majority of the market with almost all the big hospitals in tier I cities preferring to implant stents manufactured by foreign companies. Since the medical equipments and devices industry in India has not been given any separate legal status and coronary stents have been classified as drugs under the provisions of the Drugs & Cosmetics Act, 1940, the Central Drugs Standard Control Organization (CDSCO) is responsible for the regulation of stents in the country. The significant reduction in reimbursement rates for stents under the Central Government Health Scheme (CGHS) in Feb 2013 and a further reduction in the reimbursement rates in Apr 2014 has badly affected manufacturers, especially the MNCs. Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Drivers & Challenges - Government Involvement - Competitive Landscape - Buyer Details - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies: - Opto Circuits (India) Ltd. Private Companies - Abbott Healthcare Pvt. Ltd. - B. Braun Medical (India) Pvt. Ltd. - Boston Scientific India Pvt. Ltd. - India Medtronic Pvt. Ltd. - MIV Therapeutics (India) Pvt. Ltd. - Meril Life Sciences Pvt. Ltd. - Relisys Medical Devices Ltd. - Sahajanand Medical Technologies Pvt. Ltd. - Vascular Concepts Ltd. For more information visit http://www.researchandmarkets.com/research/8q...ary_stents
Transvaginal Mesh Lawsuit News: Pennsylvania Court Denies Manufacturers' Bid to Have Mesh Suits Dismissed, The Rottenstein Law Group LLP Reports
PRWeb - Mon Sep 08, 2:03PM CDT
The preliminary objections of defendant vaginal mesh manufacturers Boston Scientific Corp., Ethicon Inc., Johnson & Johnson, C.R. Bard Inc., and American Medical Systems Inc. were overruled without prejudice by the Court of Common Pleas, First Judicial District of Pennsylvania (Philadelphia) on September 2, according to an order of the court filed in In re: Pelvic Mesh Litigation (case no. 140200829). The mesh manufacturers may still seek summary judgment on a case-by-case basis.
Boston Scientific (BSX) Approaches New Upside Target of $12.34
Comtex SmarTrend(R) - Mon Sep 08, 9:28AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today above their pivot of $12.08 and have already reached the first level of resistance at $12.18. Investors may be interested in a cross of the next upside pivot targets of $12.34 and $12.60.
Australia Peripheral Vascular & Cardiovascular Procedures Devices Market Outlook to 2020 New Report Available at MarketOptimizer.org
PRWeb - Sun Sep 07, 8:30PM CDT
Australia Peripheral Vascular Devices Market Outlook to 2020
Boston Scientific Set to Possibly Rebound After Yesterday's Selloff of 1.88%
Comtex SmarTrend(R) - Fri Sep 05, 3:44PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $11.99 to a high of $12.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $12.18 on volume of 31.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Boston Scientific After 1.88% Loss
Comtex SmarTrend(R) - Fri Sep 05, 3:43PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $11.99 to a high of $12.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $12.18 on volume of 31.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
at The Street - Fri Sep 05, 5:00AM CDT
There's no compelling reason to buy this stock above $40.
Boston Scientific (BSX) Crosses Pivot Point Support at $12.35
Comtex SmarTrend(R) - Thu Sep 04, 10:13AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today below their pivot of $12.51 and have already reached the first level of support at $12.35. Should the shares continue to fall, the support pivots of $12.26 and $12.01 will be of interest.
Insider Trading Alert - NNN, WDAY And BSX Traded By Insiders
at The Street - Thu Sep 04, 9:31AM CDT
Stocks with insider trader activity include NNN, WDAY and BSX
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna
PR Newswire - Thu Sep 04, 7:40AM CDT
Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.
Market Maker Surveillance Report. BSX, SMA, EMC, BX, GCVRZ, PFMT, Bullishly Biased Price Friction For Thursday, September 11th 2014
M2 - 16 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4878 companies with "abnormal" market making, 2401 companies with positive Friction Factors and 2459 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Boston Scientific Corp (NYSE:BSX), Symmetry Medical Inc (NYSE:SMA), EMC Corp (NYSE:EMC), BIOX Corp (NYSE:BX), Sanofi SA (NASDAQ:GCVRZ), (NYSE
FMT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . Dallas Jury Awards Transvaginal Mesh Patient $73 Million in Boston Scientific Lawsuit, Baron and Budd Reports
Business Wire - Thu Sep 11, 5:10PM CDT
Earlier this week, a Dallas jury returned a $73 million verdict in favor of a woman who has suffered serious health problems after being implanted with Boston Scientific's Obtryx transvaginal mesh product. Baron and Budd congratulates Matthews & Associates, Freese and Goss, Edwards & de la Cerda and the rest of the trial team on their victory. The firm hopes that this verdict helps to pave the way for positive results in other transvaginal mesh lawsuits. Baron and Budd represents hundreds of women harmed by transvaginal mesh implants.
Texas Jury awards $73 Million in Pelvic Mesh Case, announces Matthews & Associates
PR Newswire - Wed Sep 10, 3:58PM CDT
A 12-person jury on Monday ordered Boston Scientific Corp. to pay a Texas woman $73 million after finding the company negligent in both the design and marketing of its Obtryx transvaginal mesh sling.
Watch for Boston Scientific to Potentially Pullback After Gaining 1.05% Yesterday
Comtex SmarTrend(R) - Wed Sep 10, 3:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.35 to a high of $12.55. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $12.45 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Boston Scientific to Potentially Pullback after Yesterday's 1.05% Rise
Comtex SmarTrend(R) - Wed Sep 10, 3:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.35 to a high of $12.55. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $12.45 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
pSivida Corp. Names James Barry to Board of Directors
Business Wire - Wed Sep 10, 3:00PM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected James J. Barry, Ph.D. to its Board of Directors.
Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014
PR Newswire - Wed Sep 10, 8:00AM CDT
Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in interventional cardiology. The company will share results from more than a dozen clinical studies at the 26th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation, being held this year in Washington, D.C. from September 13-17.
Market Maker Surveillance Report. WEN, BSX, MO, BA, MSFT, ORCL, Highest Net Buy Volume With Lowest Price Friction For Tuesday, September 9th 2014
M2 - Wed Sep 10, 3:39AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4670 companies with "abnormal" market making, 1404 companies with positive Friction Factors and 3746 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Tuesday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Wendy's Company (NASDAQ:WEN), Boston Scientific Corp (NYSE:BSX), Altria Group Inc (NYSE:MO), Boeing Co (NYSE:BA), MICROSOFT CORPORATION (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Halloran Consulting Group Expands Services with Physician, Safety Expert, and Head of Regulatory Affairs
Business Wire - Tue Sep 09, 9:00AM CDT
Halloran Consulting Group, Inc. (Halloran) today announced the recent hiring of Greg Shipp, MD, formerly with Regenesis Biomedical where he served as Director of Clinical Research; Laura Giannini, RPh, MBA, previously with Boston Scientific as Director of Process Management; and Mary Matthew, formerly with ZIOPHARM Oncology where she served as Vice President of Regulatory Affairs and Quality.
Coronary Stents Market in India 2014
M2 - Tue Sep 09, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qnbgv/coronary_stents) has announced the addition of the "Coronary Stents Market in India 2014" report to their offering. Advancements in technology has resulted in patients being more receptive towards stent implants. The products available in the market can be divided into two types - those manufactured by MNCs and commanding high prices, and those manufactured by domestic companies and generally having lower prices. The general perception is that stents manufactured by MNCs are superior in terms of quality and efficacy whereas those manufactured by domestic companies fail to attain similar high quality. As a result, the MNCs serve majority of the market with almost all the big hospitals in tier I cities preferring to implant stents manufactured by foreign companies. Since the medical equipments and devices industry in India has not been given any separate legal status and coronary stents have been classified as drugs under the provisions of the Drugs & Cosmetics Act, 1940, the Central Drugs Standard Control Organization (CDSCO) is responsible for the regulation of stents in the country. The significant reduction in reimbursement rates for stents under the Central Government Health Scheme (CGHS) in Feb 2013 and a further reduction in the reimbursement rates in Apr 2014 has badly affected manufacturers, especially the MNCs. Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Drivers & Challenges - Government Involvement - Competitive Landscape - Buyer Details - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies: - Opto Circuits (India) Ltd. Private Companies - Abbott Healthcare Pvt. Ltd. - B. Braun Medical (India) Pvt. Ltd. - Boston Scientific India Pvt. Ltd. - India Medtronic Pvt. Ltd. - MIV Therapeutics (India) Pvt. Ltd. - Meril Life Sciences Pvt. Ltd. - Relisys Medical Devices Ltd. - Sahajanand Medical Technologies Pvt. Ltd. - Vascular Concepts Ltd. For more information visit http://www.researchandmarkets.com/research/8q...ary_stents
Transvaginal Mesh Lawsuit News: Pennsylvania Court Denies Manufacturers' Bid to Have Mesh Suits Dismissed, The Rottenstein Law Group LLP Reports
PRWeb - Mon Sep 08, 2:03PM CDT
The preliminary objections of defendant vaginal mesh manufacturers Boston Scientific Corp., Ethicon Inc., Johnson & Johnson, C.R. Bard Inc., and American Medical Systems Inc. were overruled without prejudice by the Court of Common Pleas, First Judicial District of Pennsylvania (Philadelphia) on September 2, according to an order of the court filed in In re: Pelvic Mesh Litigation (case no. 140200829). The mesh manufacturers may still seek summary judgment on a case-by-case basis.
Boston Scientific (BSX) Approaches New Upside Target of $12.34
Comtex SmarTrend(R) - Mon Sep 08, 9:28AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today above their pivot of $12.08 and have already reached the first level of resistance at $12.18. Investors may be interested in a cross of the next upside pivot targets of $12.34 and $12.60.
Australia Peripheral Vascular & Cardiovascular Procedures Devices Market Outlook to 2020 New Report Available at MarketOptimizer.org
PRWeb - Sun Sep 07, 8:30PM CDT
Australia Peripheral Vascular Devices Market Outlook to 2020
Boston Scientific Set to Possibly Rebound After Yesterday's Selloff of 1.88%
Comtex SmarTrend(R) - Fri Sep 05, 3:44PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $11.99 to a high of $12.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $12.18 on volume of 31.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Boston Scientific After 1.88% Loss
Comtex SmarTrend(R) - Fri Sep 05, 3:43PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $11.99 to a high of $12.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $12.18 on volume of 31.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
at The Street - Fri Sep 05, 5:00AM CDT
There's no compelling reason to buy this stock above $40.
Boston Scientific (BSX) Crosses Pivot Point Support at $12.35
Comtex SmarTrend(R) - Thu Sep 04, 10:13AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today below their pivot of $12.51 and have already reached the first level of support at $12.35. Should the shares continue to fall, the support pivots of $12.26 and $12.01 will be of interest.
Insider Trading Alert - NNN, WDAY And BSX Traded By Insiders
at The Street - Thu Sep 04, 9:31AM CDT
Stocks with insider trader activity include NNN, WDAY and BSX
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna
PR Newswire - Thu Sep 04, 7:40AM CDT
Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.
